1. To characterize the durability of response of risankizumab measured by the proportion of patients
achieving a PASI90 at month 4 and maintaining it after 3 years in the management of adult patients
with moderate to severe chronic plaque psoriasis.
2. To evaluate the time to first treatment change (including discontinuation, dose escalation and dosing
interval shortening) of risankizumab compared to other commonly used biologics in the management
of adult patients with moderate to severe chronic plaque psoriasis.